Two-Year Outcomes of "Treat and Extend" Intravitreal Therapy for Neovascular Age-Related Macular Degeneration
Jennifer J Arnold, Anna Campain, Daniel Barthelmes, Judy M Simpson, Robyn H Guymer, Alex P Hunyor, Ian L McAllister, Rohan W Essex, Nigel Morlet, Mark C Gillies
OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2015
PURPOSE: To report 24-month outcomes of anti-vascular endothelial growth factor (VEGF) therapy for treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) using a treat and extend treatment regimen in routine clinical practice. DESIGN: Database observational study. PARTICIPANTS: We included treatment-naïve eyes receiving predominantly ranibizumab for nAMD in routine clinical practice treated using a treat and extend regimen that were tracked in the Fight Retinal Blindness observational registry. METHODS: A cohort of eyes treated by practitioners using exclusively a treat and extend regimen was extracted from the Fight Retinal Blindness observational registry. MAIN OUTCO..View full abstract
Awarded by National Health and Medical Research Council, Australia (NHRMC)
Supported by a grant from the Royal Australian NZ College of Ophthalmologists Eye Foundation (2007-2009) and a grant from the National Health and Medical Research Council (grant no. 632663), Australia (NHRMC 2010-2012). The authors state they have no conflicts of interest to declare. Mark Gillies is a Sydney Medical Foundation Fellow and is supported by an NHMRC practitioner fellowship.